Myostin Therapeutics Pty Ltd entered into a conditional Share Sale Agreement to acquire Omniblend Innovation Pty Ltd from EVE Health Group Limited (ASX:EVE) and other shareholders on September 16, 2022. EVE's portion of the proceeds of the share sale are approximately AUD 0.30 million. Omni Innovation shareholders, including EVE, are to receive a distribution of net cash held by Omni Innovation at completion.

The agreement is binding but conditional on Myostin Therapeutics Pty Ltd raising a minimum of $850,000 by the Completion Date of December 15, 2022. As of December 20, 2022, Myostin Therapeutics Pty Ltd completed the acquisition of 38% stake in Omniblend Innovation Pty Ltd from EVE Health. EVE's portion of the proceeds of the share sale and distribution of net cash proceeds are approximately $330,000.